• Methods: Between October 1998 and February 2004, 668 patients with newly diagnosed multiple myeloma received two cycles of intensive melphalan-based chemotherapy, each supported by autologous hematopoietic stem-cell transplantation. (elsevierpure.com)
  • We retrospectively analyzed clinical characteristics, response to treatment and survival of 282 patients with active newly-diagnosed multiple myeloma, comparing results between patients younger and older than 65 years. (scielo.br)
  • Review of 1027 patients with newly diagnosed multiple myeloma. (scielo.br)
  • Design and Methods Oral cyclophosphamide, thalidomide, and dexamethasone was compared with infusional cyclophosphamide, vincristine, doxorubicin, and dexamethasone in patients with newly diagnosed multiple myeloma. (haematologica.org)
  • Based on its oral administration and the reduced incidence of infection and cytopenia, cyclophosphamide-thalidomide-dexa-methasone may be considered an effective induction therapy option for patients with newly diagnosed multiple myeloma. (haematologica.org)
  • High-dose therapy (HDT) combined with autologous stem-cell transplantation (ASCT) provides superior response and survival outcomes versus standard chemotherapy in patients with newly diagnosed (ND) multiple myeloma (MM). 1 , 2 Standard induction chemotherapy regimens, however, are often associated with hematologic stem-cell toxicity, which may compromise the collection of stem cells for ASCT. (haematologica.org)
  • Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm. (cancernetwork.com)
  • The healthcare executive must rely on hematologists and pharmacists to review, discuss, and recommend the drugs and procedures for newly diagnosed multiple myeloma through last therapy. (managedhealthcareexecutive.com)
  • Frailty score predicts outcome in transplant-ineligible patients with newly diagnosed myeloma and is incorporated into the staging criteria. (medscape.com)
  • Participants aged =18 with Newly Diagnosed Multiple Myeloma (NDMM) who has received induction therapy followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT), without subsequent consolidation or maintenance. (who.int)
  • Graft-versus-host disease (GVHD) remains a significant complication in patients undergoing allogeneic stem cell transplantation (SCT) using a reduced intensity conditioning regimen. (qub.ac.uk)
  • Their ongoing Phase 2 study is evaluating whether infusion of mesenchymal stem cells (MSCs) can treat steroid-resistant acute graft-versus-host disease (GVHD) or poor graft function after HSCT. (drugdiscoverynews.com)
  • ide-cel) as the first B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. (drugs.com)
  • CAR T cell therapies have shown transformational potential for the treatment of hematologic malignancies, and we, with our partners at bluebird bio, are proud to bring the first CAR T cell therapy to appropriate triple-class exposed patients with relapsed or refractory multiple myeloma, offering the chance for durable response," said Samit Hirawat, M.D., chief medical officer, Bristol Myers Squibb. (drugs.com)
  • 4-9 Patients with relapsed or refractory multiple myeloma that have been exposed to all three major drug classes (triple-class exposed), including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody, tend to demonstrate poor clinical outcomes with very low response rates (20% to 30%), short duration of response (2 to 4 months) and poor survival. (drugs.com)
  • As a treating physician, I often work with patients with relapsed or refractory multiple myeloma who are in critical need of new therapies. (drugs.com)
  • It is indicated as monotherapy, in combination with dexamethasone, or in combination with lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma in patients who have received at least 1 prior line of therapy. (medscape.com)
  • The diagnosis was established according to International Myeloma Working Group criteria [ 12 ]. (jcancer.org)
  • In the KarMMa study, ide-celelicited rapid responses in the majority of patients, and these deep and durable responses were observed in patients with triple-class exposed and refractory multiple myeloma," said Nikhil C. Munshi, M.D., Associate Director, The Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, Boston, Massachusetts. (drugs.com)
  • Blenrep improves durability and provides meaningful response rates to patients with relapsed/refractory multiple myeloma, researchers found. (curetoday.com)
  • Research Objective We will use integrated gene editing techniques to develop a new CAR-T cell therapy for multiple myeloma treatment Impact Develop an improved CAR-T cell therapy for patients with refractory multiple myeloma and a new manufacturing strategy that circumvents the costs and inefficiencies of viral production. (ca.gov)
  • The choice of chemotherapy depends on several factors, including the patient's performance status, age, renal function, desire for inpatient or outpatient therapy, and likelihood of receiving future autologous stem cell transplantation. (medscape.com)
  • Ablative (myeloablative) treatment -- High-dose chemotherapy, radiation, or both are given to kill any cancer cells. (medlineplus.gov)
  • Stem cells are removed from you before you receive high-dose chemotherapy or radiation treatment. (medlineplus.gov)
  • After high-dose chemotherapy or radiation treatments, your stems cells are put back in your body to make normal blood cells. (medlineplus.gov)
  • A stem cell transplant is usually done after chemotherapy and radiation is complete. (medlineplus.gov)
  • In recent years, with a combination of autologous stem-cell transplantation and modern chemotherapy, the 10-y survival of patients presenting at an age less than 60 y is approximately 30% ( 1 , 2 ). (snmjournals.org)
  • The more aggressive forms of hematopoietic and lymphoid tissue diseases require treatment with chemotherapy, radiotherapy, immunotherapy and, in some cases, a bone marrow transplant. (atlasantibodies.com)
  • High-dose melphalan followed by autologous stem cell transplant after induction has been associated with superior event-free survival compared with chemotherapy and is considered the preferred approach. (medscape.com)
  • Hematopoietic stem cell transplantation is also sometimes used for solid tumors (eg, some germ cell tumors) that respond to chemotherapy. (msdmanuals.com)
  • [ 2 ] Options for second-line therapy in patients with relapsed/refractory disease include chemotherapy-free regimens with biologic targeted agents such as covalent Bruton tyrosine kinase (BTK) inhibitors, lenalidomide,venetoclax, and chimeric antigen receptor (CAR) T-cell therapy. (medscape.com)
  • Body iron disorders have been reported after myeloablative conditioning in patients undergoing hematopoietic stem cell transplantation (HSCT). (karger.com)
  • His research focus is on haematopoietic stem cell transplantation (HSCT) and translational research of normal and malignant stem cells. (edu.au)
  • Hematopoietic stem cell transplantation (HSCT) is a broad term that covers the transplantation of blood progenitor/stem cells from any source. (drugdiscoverynews.com)
  • Among the conditions HSCT can treat are: acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, myeloproliferative disorders, myelodysplastic syndromes, multiple myeloma, non-Hodgkin lymphoma, Hodgkin disease, aplastic anemia and pure red-cell aplasia-but this list is not exhaustive. (drugdiscoverynews.com)
  • Other groups are also working on cell therapies for the treatment of poor graft function after HSCT. (drugdiscoverynews.com)
  • Hematopoietic stem cell transplants ("HSCTs") provide an often-curative option for many patients with hematological and oncological conditions, with multiple myeloma, Non-Hodgkin lymphoma, and acute myelogenous leukemia being the most common diseases requiring an HSCT treatment. (wivb.com)
  • Hematopoietic stem cell transplantation (HSCT) affects serious risks for the patient, including death. (bvsalud.org)
  • HSCT) has significantly modified the prognosis of when the pathological process involves BM or when patients with hereditary or acquired hematological, hematopoietic toxicity is the limiting factor in the oncological and immunological diseases and it is the aggressive treatment of the disease. (bvsalud.org)
  • HSCT make it an aggressive process, causing consists of painless intravenous infusion of healthy toxicity and can generate significant complications hematopoietic stem cells (HSC) extracted from bone and several side effects adding feelings of worry, marrow (BM), peripheral blood (PB) and placental anguish, anxiety, among others (KUBA et al. (bvsalud.org)
  • Abecma will be manufactured for each individual patient using the patient's own T cells at Bristol Myers Squibb's state-of-the-art cellular immunotherapy manufacturing facility in Summit, New Jersey. (drugs.com)
  • Hematopoietic stem cell transplantation may be autologous (using the patient's own cells) or allogeneic (using cells from a donor). (msdmanuals.com)
  • We assessed whether the addition of thalidomide, which has activity against advanced and refractory myeloma, would further improve survival. (elsevierpure.com)
  • elicits antiproliferative and proapoptotic activities in vitro in solid and hematologic tumor cells. (medscape.com)
  • Multiple myeloma (MM) represents 1% of all cancers and is the second most common hematologic malignancy, after lymphoma. (scielo.br)
  • Examples of hematologic cancer include leukemia, lymphoma, and multiple myeloma. (atlasantibodies.com)
  • Multiple Myeloma (MM) is an incurable plasma cell malignancy that accounts for 18% of all hematologic malignancies. (haematologica.org)
  • Hematologic Malignancie market report is segmented on the basis of type, therapy and by regional & country level.Based upontype, Hematologic Malignancie market is classified intoLeukemia, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Lymphoma,Multiple Myeloma and Others. (medgadget.com)
  • Multiple myeloma (MM) is a cancer of terminally differentiated plasma B cells that originates in the hematopoietic bone marrow and accounts for 15%-20% of all hematologic malignancies ( 1 , 2 ). (snmjournals.org)
  • He also has expertise with cellular therapies for hematologic malignancies, specifically chimeric antigen receptor (CAR) T-cell therapy. (lvhn.org)
  • The cells are also being evaluated in a variety of other hematologic indications. (drugdiscoverynews.com)
  • Hematologic neoplasms are abnormal and anarchic proliferations of hematopoietic cells with a medullary or peripheral starting point. (bvsalud.org)
  • In our practice, hematologic neoplasms are mainly lymphoproliferative syndromes and the most common varieties are non-Burkitt non Hodgkin lymphoma, high grade lymphomas, chronic lymphocytic lymphoma and multiple myeloma. (bvsalud.org)
  • Cancer stem cells (CSCs) are generated by a combination of DNA mutations, epigenetic events, and tissue microenvironment factors from normal stem cells or precursor/progenitor cells, to which they are closely related and share many of the behaviors and features 1 . (atlasantibodies.com)
  • It is arise from hematopoietic stem and progenitor cells in the bone marrow. (medgadget.com)
  • In a second line, we use natural genetic variation to find genes that regulate hematopoietic stem and progenitor cells (HSPC) in humans. (lu.se)
  • Prognostic factors to predict outcome of reduced intensity allogeneic haematopoietic cell transplantation for chronic lymphocytic leukemia. (nih.gov)
  • For examples include acute lymphoblastic leukemia, chronic lymphocytic leukemia, lymphomas and multiple myeloma. (medgadget.com)
  • The most commonly diagnosed blood cancers are non-Hodgkin lymphoma, chronic lymphocytic leukemia, acute myeloid leukemia, acute lymphoblastic leukemia and multiple myeloma. (medgadget.com)
  • In my first paper, we describe the entire antibody discovery process where we developed antibodies capable of depleting chronic lymphocytic leukemia (CLL) cells using primary cells obtained from patients. (lu.se)
  • [ 1 ] First described in 1848, MM is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance ( MGUS ) to plasma cell leukemia. (medscape.com)
  • Patients with monoclonal gammopathy of unknown significance, smoldering MM, plasma cell leukemia and amyloidosis were excluded. (scielo.br)
  • Multiple myeloma (MM) is a debilitating malignancy that is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance ( MGUS ) to plasma cell leukemia. (medscape.com)
  • Additionally,Leukemia is diagnosed 10 times more often in adults than children.New cases of leukemia, lymphoma and myeloma are expected to account for 10 percent of the estimated 1,762,450 new cancer cases diagnosed in the US in 2019. (medgadget.com)
  • CSCs were first identified in hematological cancer such as acute myeloid leukemia in the late '90s when scientists isolated a subpopulation of leukemia cells that expressed the surface marker CD34 but not CD38. (atlasantibodies.com)
  • Acute (AML) and chronic (CML) myeloid leukemia are cancers of the myeloid line of blood cells, characterized by the rapid growth of abnormal cells that build up in the bone marrow and blood and interfere with normal blood cell production. (atlasantibodies.com)
  • I have expertise in novel therapies for acute myeloid leukemia, stem cell mobilization and homing, as well as stem cell transplantation. (rochester.edu)
  • AXL, a tyrosine kinase receptor, is commonly overexpressed in several solid tumours and numerous hematopoietic malignancies including acute myeloid leukaemia, acute lymphocytic leukaemia, chronic myeloid leukaemia, chronic lymphocytic leukaemia and multiple myeloma. (cancerindex.org)
  • As our second FDA-approved CAR T cell therapy, Abecma underscores our commitment to deliver on the promise of cell therapies for patients who are battling aggressive and advanced blood cancers with limited effective treatment options. (drugs.com)
  • Of all the other cancers, multiple myeloma causes this complication the most. (webmd.com)
  • Similarly, curcumin, a substance found in turmeric, has some evidence supporting its use against cancers like multiple myeloma. (healthline.com)
  • For many cancers, the donor's white blood cells may attack any remaining cancer cells, which are seen as foreign, similar to when white cells attack bacteria or viruses when fighting an infection. (medlineplus.gov)
  • For lung cancers, CSC markers include CD44 and CD133 (PROM1), but also CD117 (KIT), CD90 (or THY1), CD166, EpCAM for non-small-cell lung carcinoma (NSCLC), and PODXL-1, PTCH, and CD87 for small-cell lung carcinoma (SCLC) 25 . (atlasantibodies.com)
  • Translational Candidate Lenti/iNKT-sr39TK Modified Autologous Human CD34+ Hematopoietic Stem Cells (HSCs) Area of Impact The targeted area of impact for the candidate is cancer therapy, in particular cancers that are lacking existing effective treatments. (ca.gov)
  • Despite advances in treatment, multiple myeloma remains an incurable disease characterized by periods of remission and relapse. (drugs.com)
  • Comparison of autologous hematopoietic cell transplantation performed in tandem and in disease relapse in multiple myeloma patients. (nih.gov)
  • Cancer stem cells (CSCs) are small cells, 1% to 3% of all cells in a tumor, that drive the tumor's initiation, growth, and metastasis and may cause relapse. (atlasantibodies.com)
  • In addition, CSCs might give rise to metastases, acting as a reservoir of cancer cells, causing relapse after the surgery or treatment has eliminated the visible signs of cancer. (atlasantibodies.com)
  • Area of Impact Translational candidate will enable treatment of patients with heterogeneous or BCMA- multiple myeloma and prevent cancer relapse due to antigen loss. (ca.gov)
  • Learn more about relapsed multiple myeloma and a treatment option if you relapse on REVLIMID. (revlimid.com)
  • Hematopoietic stem cell transplant. (mayoclinic.org)
  • http://www.cancer.gov/about-cancer/treatment/types/stem-cell-transplant/stem-cell-fact-sheet. (mayoclinic.org)
  • A bone marrow transplant is a procedure to replace damaged or diseased bone marrow with healthy bone marrow stem cells. (medlineplus.gov)
  • The stem cells are frozen and stored until they are needed for a transplant. (medlineplus.gov)
  • The report also includes clinical guidance for adults who have received 7-valent PCV (PCV7) only and adults who are hematopoietic stem cell transplant recipients. (cdc.gov)
  • Only patients who were not treated with autologous or allogeneic hematopoietic stem cell transplant were included. (jcancer.org)
  • Most of the patients in my clinic are blood and bone marrow transplant patients and patients with plasma cell diseases such as multiple myeloma, amyloidosis, POEMS syndrome, and Waldenstrom's macroglobulinemia. (dukehealth.org)
  • The research interests in my lab are on the development of new approaches to enhance hematopoietic stem cell engraftment and reconstitution following blood and bone marrow transplant. (dukehealth.org)
  • While many of the Cancer Institute's patients are able to receive the most advanced therapies for their diagnosis close to home, people who needed hematopoietic cell transplant or cellular immunotherapy have always needed to travel outside of the Lehigh Valley for these treatments. (lvhn.org)
  • That changes this year with the development of Lehigh Valley Topper Cancer Institute's Stem Cell Transplant and Cellular Therapy Program. (lvhn.org)
  • The Cancer Institute's membership in the Memorial Sloan Kettering Cancer Alliance will also connect the new program to additional stem cell transplant and cellular therapy education and resources. (lvhn.org)
  • Dr. Toor and Dr. Nair hope to launch the Stem Cell Transplant and Cellular Therapy Program in fall 2023. (lvhn.org)
  • Transplant Cell Ther 2021. (harvard.edu)
  • Defibrotide: Real World Management of Veno-Occlusive Disease/ Sinusoidal Obstructive Syndrome after Stem Cell Transplant. (harvard.edu)
  • First-line therapy is usually 2 or 3 drugs and, if possible, many recommend autologous hematopoietic stem cell transplant, once or more than once. (managedhealthcareexecutive.com)
  • Explore REVLIMID for multiple myeloma maintenance therapy after receiving a stem cell transplant. (revlimid.com)
  • REVLIMID ® (lenalidomide) is a prescription medicine, used to treat adults with multiple myeloma (MM) in combination with the medicine dexamethasone, or as maintenance treatment after autologous hematopoietic stem cell transplantation (a type of stem cell transplant that uses your own stem cells). (revlimid.com)
  • All transplant-eligible multiple myeloma patients should receive a triplet induction therapy (immunomodulatory agents, proteasome inhibitor and dexamethasone). (medscape.com)
  • Myeloma cells produce excess abnormal proteins, called paraproteins, in the bone marrow that can cause your blood to become so thick that it flows sluggishly in your body, a condition called hyperviscosity. (webmd.com)
  • Abnormal proteins from myeloma cells can also damage the kidneys. (webmd.com)
  • Multiple myeloma is a bone marrow disease characterized by the presence of malignant plasma cells, & abnormal serum &/or urine immunoglobulin secondary to clonal plasma cell expansion. (mims.com)
  • There was an increased incidence of venous and arterial thrombotic events in patients with multiple myeloma who received lenalidomide in combination with dexamethasone compared with dexamethasone alone in clinical trials. (pdr.net)
  • It is indicated in combination with bortezomib and dexamethasone for treatment of multiple myeloma in patients who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent. (medscape.com)
  • One trial is testing whether MSCs with or without peripheral blood stem cells could treat poor graft function and delayed platelet engraftment. (drugdiscoverynews.com)
  • In another trial, this group is evaluating whether peripheral blood stem cells combined with MSCs can treat poor graft function. (drugdiscoverynews.com)
  • Calebin-A induced death of malignant peripheral nerve sheath tumor cells by activation of histone acetyltransferase. (cancerindex.org)
  • Plerixafor injection is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM). (fresenius-kabi.com)
  • Several drug therapies are valuable in the treatment of symptomatic MM. Clinicians treat many patients with high-dose therapy and peripheral blood or bone marrow stem cell transplantation. (medscape.com)
  • Peripheral blood has largely replaced bone marrow as a source of stem cells, especially in autologous hematopoietic stem cell transplantation, because stem cell harvest is easier and neutrophil and platelet counts recover faster. (msdmanuals.com)
  • Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice. (cancernetwork.com)
  • The existence of stem cells in hematological tissue prompted research in other tissue cancer types. (atlasantibodies.com)
  • Conclusions: When incorporated into high-dose therapy for myeloma, thalidomide increased the frequency of complete responses and extended event-free survival at the expense of added adverse effects without improving overall survival. (elsevierpure.com)
  • Abecma is a personalized immune cell therapy approved as a one-time infusion with a recommended dose range of 300 to 460 x 10 6 CAR-positive T cells. (drugs.com)
  • 1 As an anti-BCMA CAR T cell therapy, Abecma recognizes and binds to BCMA, a protein that is nearly universally expressed on cancer cells in multiple myeloma, leading to the death of BCMA-expressing cells. (drugs.com)
  • Now, with the approval of ide-celas the first anti-BCMA CAR T cell therapy, we are excited to finally be able to offer patients a new, effective personalized treatment option that is delivered through a single infusion. (drugs.com)
  • Wollert, K. C. & Drexler, H. Cell therapy for the treatment of coronary heart disease: A critical appraisal. (nature.com)
  • The intrinsic immune dysfunction in combination with therapy-related immunosuppression leads to an increased risk for infections, which is a hallmark of multiple myeloma (MM) and major cause of mortality [ 1 - 5 ]. (jcancer.org)
  • Experts in the field of multiple myeloma gathered to discuss considerations prior to treatment including frailty and the number of lines of previous therapy a patient has received. (cancernetwork.com)
  • Experts in the field of multiple myeloma gathered to discuss treatment options, including bispecific antibodies, CAR T-cell therapy, and current and future FDA approvals for treatments. (cancernetwork.com)
  • Translational Candidate A single-chain bispecific chimeric antigen receptor (CAR) targeting BCMA and CS1 will be used to in autologous T-cell therapy for multiple myeloma. (ca.gov)
  • This means more therapy, more often, and thus, potential financial ramifications for payers of myeloma treatment," Messerschmidt said. (managedhealthcareexecutive.com)
  • The approval of new drugs continues to change the landscape of myeloma maintenance therapy. (medscape.com)
  • In general, the first decision made in the management of patients with myeloma who require systemic therapy is whether stem cell transplantation is part of the strategy. (medscape.com)
  • Patients who present with active (symptomatic) multiple myeloma are treated with induction therapy. (medscape.com)
  • Participant has previous history of an allogeneic hematopoietic stem cell transplantation or treatment with any gene therapy-based therapeutic for cancer or investigational cellular therapy for cancer or B-cell maturation antigen targeted therapy. (who.int)
  • One crucial ability of the CSCs is to form tumors already at low cell numbers. (atlasantibodies.com)
  • On the other hand, in brain tumors, such as glioma and glioblastoma, CSCs have instead been identified using cell surface markers, including SSEA-1 20 , EGFR 21 , and CD44 22 . (atlasantibodies.com)
  • Furthermore, the infection itself can pathogenetically contribute to the progression of MM through different mechanisms, such as robust production of promyeloma cytokines (e.g., interleukin-6) and activation of Toll-like receptors on malignant plasma cells [ 6 - 10 ]. (jcancer.org)
  • First described in 1848, MM is characterized by a proliferation of malignant plasma cells and a subsequent overabundance of monoclonal paraprotein (M protein). (medscape.com)
  • These mental health issues may be due to living with the illness or health problems that you may get because of myeloma medicines or treatment. (webmd.com)
  • Myeloma and treatment for myeloma can weaken your immunity , making the body prone to many infections. (webmd.com)
  • It is indicated for the palliative treatment of multiple myeloma. (medscape.com)
  • Is there a place for complementary therapies in multiple myeloma treatment? (healthline.com)
  • The Food and Drug Administration granted an investigational new drug application and green lit the continued study of GC012F for the treatment of patients with relapsed/refractory myeloma. (curetoday.com)
  • The second area of my research is to identify molecules and pathways that can be used as biomarkers for treatment responses and as therapeutic targets for the treatment of multiple myeloma. (dukehealth.org)
  • Given the strong efficacy data shown in the GENESIS trial, which included patients who are representative of the current multiple myeloma patient population, we believe [motixafortide] will play a critical role in addressing unmet needs and introduce a new treatment paradigm for this challenging cancer," Serlin stated. (cancernetwork.com)
  • The current treatment for incomplete hematopoietic recovery includes administration of factors stimulating white and red blood cell growth, such as granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF) and erythropoietin. (drugdiscoverynews.com)
  • Hear patients with multiple myeloma talk about their treatment journeys. (revlimid.com)
  • Find multiple myeloma treatment resources available to share and download. (revlimid.com)
  • Multiple myeloma treatment can be complicated. (revlimid.com)
  • White blood cell counts should be monitored during treatment. (fresenius-kabi.com)
  • Treatment protocols for multiple myeloma are provided below. (medscape.com)
  • Understanding how HSPCs are regulated is of central importance for several areas in clinical hematology, including stem cell transplantation and the treatment of leukemias. (lu.se)
  • These problems can be partially circumvented by using macroporous biomaterials that improve the survival of transplanted stem cells and provide molecular cues to direct cell phenotype. (nature.com)
  • Reversible proteasome inhibition disrupts pathways supporting cell growth, thus decreasing cancer cell survival. (medscape.com)
  • Multivariable analysis revealed that creatinine ≥2 mg/dl, extramedullary disease, ≤very good partial remission and non-autologous hematopoietic stem cell transplantation are independent risk factors for shorter survival. (scielo.br)
  • Although multiple myeloma patients younger than 66 years of age have an aggressive presentation, this did not translate into an inferior overall survival, particularly in those undergoing autologous hematopoietic stem cell transplantation. (scielo.br)
  • Outcome and survival of myeloma patients diagnosed 2008-2015. (scielo.br)
  • Multiple myeloma: 2014 update on diagnosis, risk-stratification, and management. (scielo.br)
  • It came as no surprise that when my mother received a diagnosis of multiple myeloma, she became an advocate for health equity in myeloma. (curetoday.com)
  • But then, just a year after earning her doctorate, she received a diagnosis of multiple myeloma. (curetoday.com)
  • Of these, 27.91% had a main diagnosis indicating the transplantation of Multiple Myeloma (MM), and 58.14 received autologous transplantation. (bvsalud.org)
  • Sural nerve biopsies from patients with diabetes have demonstrated changes suggestive of microvascular insufficiency, including membrane basement thickening, endothelial cell proliferation, and vessel occlusions. (medscape.com)
  • Figure 2: Manipulating stem cell osteogenesis and proliferation by controlling the elasticity of the bulk phase of void-forming hydrogels. (nature.com)
  • Multiple myeloma (MM) , also known as plasma cell myeloma , is a multifocal proliferation of plasma cells based in the bone marrow . (radiopaedia.org)
  • It arises from red marrow due to the monoclonal proliferation of plasma cells and manifests in a wide range of radiographic abnormalities. (radiopaedia.org)
  • Recent studies have revealed that AXL contributes to leukaemic phenotypes through activation of oncogenic signalling pathways that lead to increased cell migration and proliferation. (cancerindex.org)
  • The FDA has approved Aphexda plus filgrastim for the mobilization of hematopoietic stem cells in patients with multiple myeloma. (curetoday.com)
  • Innovation in this area of medicine has been needed, and today's approval of [motixafortide] addresses the demand for new therapies that can meet today's challenges by delivering more reliability in stem cell mobilization, [vs] filgrastim alone, with fewer days of apheresis sessions and fewer doses of filgrastim for people living with this cancer. (cancernetwork.com)
  • Plerixafor may cause mobilization of leukemic cells and subsequent contamination of the apheresis product. (fresenius-kabi.com)
  • In patients treated with Plerixafor in combination with G-CSF for HSC mobilization, tumor cells may be released from the marrow and subsequently collected in the leukapheresis product. (fresenius-kabi.com)
  • Also, myeloma complications like kidney damage, frequent infections, high blood calcium, and more may change how well your brain works. (webmd.com)
  • There are complications of serial transfusions of either of these cell types, and a patient needs intense prophylactic treatments to protect from infections if his or her white counts are low. (drugdiscoverynews.com)
  • Our journey to today's approval of Abecma started nearly a decade ago with pioneering research at bluebird bio and has been driven ever since by our mission to provide patients with multiple myeloma a new approach to fight this relentless disease. (drugs.com)
  • Bortezomib is indicated for patients with multiple myeloma. (medscape.com)
  • The recent FDA approval of Aphexda combined with filgrastim improved the collection of stem cells in patients with multiple myeloma. (curetoday.com)
  • Based on our earlier research into the main characteristics and risk factors for infections in hospitalized patients with multiple myeloma, we created the numerical Multiple Myeloma Index for Risk of Infection (MMIRI) to predict infection in myeloma patients. (jcancer.org)
  • A single dose of motixafortide results in achievement of stem cell collection goal in patients with multiple myeloma. (cancernetwork.com)
  • The first part of the study focused on determining dosage and included 12 patients with multiple myeloma. (cancernetwork.com)
  • BioLineRx announces FDA approval of APHEXDA™ (motixafortide) in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells for collection and subsequent autologous transplantation in patients with multiple myeloma. (cancernetwork.com)